



Publication regarding Imarikiren (SCO-272)

SCOHIA PHARMA, Inc. is pleased to announce the publication of the phase 2 dose-finding study of Imarikiren (development code: SCO-272) in patients with type 2 diabetes mellitus and microalbuminuria in the *Clinical Journal of the American Society of Nephrology (CJASN)*.

Ito S, Kagawa T, Saiki T, Shimizu K, Kuroda S, Sano Y, *et al.* Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial. *Clin J Am Soc Nephrol.* 2019 Feb 12. [Epub ahead of print]

Regarding clinical studies of Imarikiren, the following four reports have already been published.

Gebremichael Y, Lahu G, Vakilynejad M, Hallow KM. Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling. *J Pharmacokinet Pharmacodyn.* 2019 Feb;46(1):15-25.

Shimasaki Y, Sakaki M, Itou M, Kobayashi T, Aso M, Kagawa T, *et al.* Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment. *Clin Drug Investig.* 2018 Nov;38(11):1041-1051.

Matsuno K, Kuroda S, Tanaka S, Nakamichi H, Kagawa T, Koumura E. Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects. *Basic Clin Pharmacol Toxicol.* 2018 Nov;123(5):607-614.

Matsuno K, Tanaka S, Hashimoto T, Nakamichi H, Kagawa T, Koumura E. A Randomized, Single-Center, Double-Blind, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects. *J Clin Pharmacol.* 2018 Nov;58(11):1516-1524.

Contact for inquiries: [info@scohia.com](mailto:info@scohia.com)